See more : Grom Social Enterprises, Inc. (GROMW) Income Statement Analysis – Financial Results
Complete financial analysis of Ergomed plc (ERGO.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ergomed plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Capital Engineering Network Public Company Limited (CEN.BK) Income Statement Analysis – Financial Results
- IRIS Business Services Limited (IRIS.NS) Income Statement Analysis – Financial Results
- Algoma Central Corporation (AGMJF) Income Statement Analysis – Financial Results
- Bougainville Copper Limited (BOC.AX) Income Statement Analysis – Financial Results
- Glory Forever Public Company Limited (GLORY.BK) Income Statement Analysis – Financial Results
Ergomed plc (ERGO.L)
About Ergomed plc
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Services and Pharmacovigilance. The company provides and manages clinical development, post-approval management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. The company also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 145.26M | 118.58M | 86.39M | 68.26M | 54.11M | 47.62M | 39.23M | 30.18M | 21.16M | 19.23M | 14.61M | 12.07M |
| Cost of Revenue | 86.12M | 70.22M | 46.74M | 38.73M | 34.86M | 33.00M | 27.24M | 21.81M | 15.39M | 12.48M | 10.69M | 8.11M |
| Gross Profit | 59.15M | 48.36M | 39.65M | 29.53M | 19.25M | 14.62M | 11.99M | 8.37M | 5.77M | 6.76M | 3.93M | 3.96M |
| Gross Profit Ratio | 40.72% | 40.78% | 45.90% | 43.26% | 35.58% | 30.70% | 30.57% | 27.74% | 27.27% | 35.14% | 26.87% | 32.78% |
| Research & Development | 121.00K | 130.00K | 152.00K | 545.00K | 1.58M | 2.69M | 1.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 19.58M | 16.70M | 9.73M | 8.32M | 5.19M | 3.68M | 5.97M | 3.42M | 3.29M |
| Selling & Marketing | 36.07M | 27.74M | 24.59M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 36.07M | 27.74M | 24.59M | 19.58M | 16.70M | 9.73M | 8.32M | 5.19M | 3.68M | 5.97M | 3.42M | 3.29M |
| Other Expenses | 2.41M | 823.00K | 235.00K | 1.49M | 2.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 38.60M | 28.69M | 24.98M | 21.61M | 20.28M | 14.50M | 10.41M | 5.99M | 4.41M | 6.05M | 3.46M | 3.34M |
| Cost & Expenses | 124.72M | 98.91M | 71.72M | 60.34M | 55.14M | 47.50M | 37.64M | 27.80M | 19.79M | 18.53M | 14.15M | 11.45M |
| Interest Income | 0.00 | 1.00K | 8.00K | 28.00K | 23.00K | 3.00K | 2.00K | 1.00K | 0.00 | 4.00K | 10.00K | 14.00K |
| Interest Expense | 613.00K | 361.00K | 403.00K | 273.00K | 619.00K | 583.00K | 274.00K | 1.00K | 2.00K | 3.00K | 0.00 | 1.00K |
| Depreciation & Amortization | 7.20M | 5.05M | 5.99M | 3.71M | 411.00K | 1.63M | 1.03M | 713.00K | 518.00K | 63.00K | 57.00K | 51.00K |
| EBITDA | 26.07M | 24.72M | 19.52M | 11.65M | -619.00K | 1.79M | 2.62M | 3.10M | 1.88M | 797.00K | 531.00K | 685.00K |
| EBITDA Ratio | 17.95% | 20.85% | 22.60% | 17.07% | -1.14% | 3.76% | 6.67% | 10.26% | 8.89% | 4.14% | 3.63% | 5.68% |
| Operating Income | 18.87M | 19.67M | 13.53M | 7.94M | -1.03M | -3.90M | 598.00K | 2.07M | 779.00K | 707.00K | 465.00K | 620.00K |
| Operating Income Ratio | 12.99% | 16.59% | 15.67% | 11.63% | -1.90% | -8.20% | 1.52% | 6.87% | 3.68% | 3.68% | 3.18% | 5.14% |
| Total Other Income/Expenses | -920.00K | -5.41M | -906.00K | -2.95M | -9.74M | -543.00K | -272.00K | 0.00 | -2.00K | 1.00K | 9.00K | 13.00K |
| Income Before Tax | 17.95M | 14.26M | 12.63M | 4.99M | -10.77M | -4.45M | 326.00K | 2.07M | 777.00K | 708.00K | 474.00K | 633.00K |
| Income Before Tax Ratio | 12.36% | 12.03% | 14.62% | 7.30% | -19.90% | -9.34% | 0.83% | 6.87% | 3.67% | 3.68% | 3.24% | 5.25% |
| Income Tax Expense | 2.97M | 1.59M | 2.95M | -583.00K | -1.79M | 57.00K | -153.00K | 520.00K | 199.00K | 352.00K | 83.00K | 98.00K |
| Net Income | 14.98M | 12.67M | 9.68M | 5.57M | -8.98M | -4.50M | 479.00K | 1.55M | 578.00K | 356.00K | 391.00K | 535.00K |
| Net Income Ratio | 10.31% | 10.69% | 11.21% | 8.16% | -16.60% | -9.46% | 1.22% | 5.14% | 2.73% | 1.85% | 2.68% | 4.43% |
| EPS | 0.30 | 0.26 | 0.20 | 0.12 | -0.20 | -0.11 | 0.01 | 0.05 | 0.02 | 0.08 | 0.02 | 0.02 |
| EPS Diluted | 0.29 | 0.25 | 0.19 | 0.11 | -0.20 | -0.10 | 0.01 | 0.05 | 0.02 | 0.07 | 0.02 | 0.02 |
| Weighted Avg Shares Out | 49.78M | 48.47M | 48.32M | 46.60M | 44.69M | 41.09M | 35.57M | 28.75M | 24.08M | 20.00M | 20.00M | 28.75M |
| Weighted Avg Shares Out (Dil) | 51.29M | 50.57M | 50.50M | 48.63M | 44.85M | 43.36M | 37.06M | 29.77M | 25.07M | 20.94M | 20.94M | 28.75M |
Source: https://incomestatements.info
Category: Stock Reports